

August 19, 2021

Sumitomo Dainippon Pharma Co., Ltd.

## **Sumitomo Dainippon Pharma Announces Transfer of Shares of its Indirectly-Owned Subsidiary in Europe**

Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura; Securities Code: 4506, First Section of TSE) announced today that, effective August 17, 2021, its U.S. consolidated subsidiary Sunovion Pharmaceuticals Inc. (hereinafter, "Sunovion") has signed an agreement on the transfer of all the shares of its wholly-owned direct subsidiary, Sunovion Pharmaceuticals Europe Ltd. (hereinafter, "SPE"), to a special purpose acquisition company ultimately controlled by Inflexion Private Equity Partners LLP (Head Office: London, U.K.; hereinafter, "Inflexion") and the share transfer has been completed as of the same date.

### 1. Reasons for the share transfer

SPE began marketing LATUDA<sup>®</sup>, an atypical antipsychotic that has been a mainstay among products of the Sumitomo Dainippon Pharma Group, in Europe in 2014. After a comprehensive evaluation of SPE's current operational status and future business opportunities, a decision has been made to transfer all the shares of SPE to Inflexion.

Sumitomo Dainippon Pharma and SPE have signed a license and supply agreement for LATUDA<sup>®</sup> in Europe, which allows Inflexion to leverage SPE's business infrastructure and employees to continuously market LATUDA<sup>®</sup> in Europe.

Sumitomo Dainippon Pharma Group will continue to pursue its global strategy, which focuses on direct sales in the markets of Japan, North America, and China and other Asian countries, while maximizing growth in collaboration with partners in Europe and other regions.

### 2. About SPE

(1)	Company name	Sunovion Pharmaceuticals Europe Ltd.
(2)	Address	London, U.K.
(3)	Lines of business	Manufacture and marketing of ethical pharmaceutical drugs in Europe
(4)	Established in	May 1997
(5)	Number of employees	29 (as of March 31, 2021)
(6)	Net sales in FY2020	28 million US dollars
(7)	Ownership structure	Sunovion Pharmaceuticals Inc.: 100%

### 3. About Inflexion

(1)	Company name	Inflexion Private Equity Partners LLP
(2)	Address	London, U.K.

(3)	Representative	Simon Turner and John Hartz, Managing Partners
(4)	Lines of business	Private equity
(5)	Established in	1999
(6)	Funds under management	5.4 billion pounds

#### 4. Future outlook

The impact of the transfer of shares on our consolidated earnings results for the year ending March 31, 2022 will be minimal.

#### Contact

Corporate Communications

Sumitomo Dainippon Pharma Co., Ltd.

TEL: +81-6-6203-1407 (Osaka); +81-3-5159-3300 (Tokyo)